Spravato Insurance Coverage in 2026: What Has Changed

spravatoinsurancecoveragemedicareprior authorizationtreatment-resistant depression

One of the most common questions people ask about Spravato is whether their insurance will cover it. The answer has become somewhat clearer since the medication’s 2019 approval, but navigating coverage still requires patience and preparation. This post outlines the current coverage landscape as of 2026 and what patients and families can realistically expect.

The Billing Landscape: How Spravato Gets Coded

Understanding coverage starts with understanding how Spravato is billed. Because treatment involves both the drug itself and a supervised administration session, there are multiple billing components that a certified clinic typically submits:

  • S0013 — HCPCS code for Spravato (esketamine nasal spray) per dose
  • G2082 — Spravato administration, first 2 hours
  • G2083 — each additional 30 minutes of monitoring beyond the first 2 hours
  • 99213 / 99214 — evaluation and management visit codes for the clinical assessment before and after dosing
  • 90791 — psychiatric diagnostic evaluation, used for the initial assessment visit

Payers differ in how they handle each of these components. Some insurers bundle the drug and administration. Others require separate submissions. Getting these codes right from the first claim is important — billing errors are one of the more common reasons for initial denials that have nothing to do with medical necessity.

The CMS reimbursement guidelines provide the federal framework for Medicare and Medicaid billing, and many commercial insurers reference CMS standards when writing their own policies.

Medicare Coverage in 2026

Medicare has covered Spravato for treatment-resistant depression under Part B for several years. Part B covers drugs administered in an office setting, which aligns with Spravato’s REMS-required supervised administration model. Medicare Advantage plans are required to cover the same benefits as Original Medicare at minimum, though cost-sharing structures vary by plan.

For Medicare beneficiaries, the key requirements remain consistent: a diagnosis of treatment-resistant depression (ICD-10 F33.2 is typically required for recurrent major depressive disorder with severe episode; F32.9 may be used for single episodes), documentation of at least two failed adequate antidepressant trials, and treatment at a REMS-certified facility.

Medicare does not typically require prior authorization for Spravato at the same level that some commercial plans do, but documentation of medical necessity must be present in the chart. Clinicians who do thorough intake assessments and maintain detailed records of prior treatment history are better positioned to support claims if they are reviewed.

Commercial Insurance: Prior Authorization Is the Rule

Most commercial insurance plans that cover Spravato require prior authorization before treatment begins. The criteria vary by insurer, but common requirements include:

  • A confirmed diagnosis of major depressive disorder, treatment-resistant
  • Documentation of at least two antidepressant trials (specific requirements on duration and dose vary — some require 6 weeks at therapeutic dose, others specify 8 weeks)
  • A prescription from a board-certified psychiatrist or other qualified clinician
  • Treatment at a REMS-certified site

Prior authorization timelines vary. Some plans respond within a few business days. Others may take two to three weeks, particularly if additional clinical documentation is requested. Clinicians and their billing teams often submit a letter of medical necessity alongside the standard prior auth form to reduce back-and-forth.

Denials on first submission happen more frequently than they should. Many of these are successfully overturned on appeal when the clinical documentation is thorough. Patients should ask their prescribing clinic about their prior authorization process and typical timelines before scheduling the first session.

What Has Changed Since Spravato’s Approval

In 2019 and 2020, coverage was less consistent. Many commercial plans had not yet developed formal Spravato policies, and billing uncertainty was common. By 2026, the situation has stabilized considerably:

Many regional and national commercial plans now have established Spravato coverage policies, which at minimum provides clarity about what documentation is needed. The criteria are more predictable even when they are strict.

Medicare has processed substantial Spravato claims over several years, and the G2082/G2083 administration codes are well-established in the CMS system. Certified clinics have more experience with the billing workflow.

Medicaid coverage varies significantly by state. Some state Medicaid programs cover Spravato; others have not yet established a coverage pathway. Patients on Medicaid should verify directly with their state program and with the treating clinic before assuming coverage.

Out-of-Pocket Costs and Manufacturer Assistance

For patients with commercial insurance who meet coverage criteria, out-of-pocket costs depend on the plan’s cost-sharing structure — deductible, copay, or coinsurance. High-deductible plans may result in significant out-of-pocket costs early in the plan year until the deductible is met.

Janssen offers a patient assistance program for Spravato. Eligibility and program details change over time; patients should ask about this directly with their clinic’s financial coordinator or contact Janssen directly. For patients who do not have coverage and cannot afford the medication, manufacturer assistance programs can make a significant difference.

Preparing for the Coverage Conversation

Before your first appointment at a Spravato clinic, gathering the following documentation will help expedite prior authorization and reduce delays:

  • Names and doses of all antidepressants previously tried, with approximate dates and duration
  • Names of all prescribing clinicians (for NPPES NPI verification if needed)
  • Your insurance card and the insurer’s prior authorization phone number
  • Any existing psychiatric records from recent treatment

The path to coverage is navigable for many patients, but it requires organized documentation and a clinic that has experience with the process. Reach out to our team to discuss how we support patients through the authorization process.

This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.

Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.